Toxicology Report

Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -

Creosote Oil Acenaphthene Fraction

What is Creosote Oil Acenaphthene Fraction?

CAS No: 90640-84-9

Creosote Oil Acenaphthene Fraction is a defined chemical entity of pharmaceutical relevance whose identity, purity, and physicochemical properties are specified per ICH Q6A standards or equivalent pharmacopoeial monograph requirements. Its solubility, lipophilicity, and ionisation state govern formulation compatibility, bioavailability, and environmental distribution behaviour. PDE derivation for Creosote Oil Acenaphthene Fraction requires systematic review of acute, repeat-dose, genotoxicity, reproductive toxicity, and carcinogenicity data, identifying the most sensitive adverse effect endpoint and the species-specific NOAEL that forms the point of departure for calculation.

Study duration uncertainty factor F3 in PDE derivation for Creosote Oil Acenaphthene Fraction compensates for the data gap between the duration of available toxicology studies and the chronic lifetime pharmaceutical exposure scenario.

To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).

Request Your Assessment

Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.

View Inquiry List →
What's included:
Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
9,000+
Toxicological & Exposure
Assessment Reports Delivered
70+
Subject Matter Experts
across global operations
12
In-House Ex-Agency
Toxicologists
3
Certification Bodies:
ERT · UKRT · DABT

Assessment Methodology

Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.

EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)

Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.

PIC/S – Shared Facilities and Contamination Control Guidance

Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.

ICH Q9 – Quality Risk Management

Provides a structured methodology for risk identification, assessment, control, communication, and review.

ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)

Applied for compounds with potential mutagenic or genotoxic concerns.

Risk-Based Toxicological Assessment

Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.

Weight-of-Evidence (WoE) Approach

Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.

Report Preparation Process

Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.

01

Comprehensive Data Review

Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.

02

Scientific Evaluation

Identification of critical endpoints and selection of appropriate exposure limits.

03

PDE / HBEL Derivation

Transparent and scientifically justified calculations aligned with global toxicological principles.

04

Ex-Agency Expert Review (Our Differentiator)

Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.

05

Final Report Delivery

Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).

Why Masuu Global?

Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.

✓

Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.

✓

Inspection-ready reports — scientifically defensible and audit-prepared from day one.

✓

Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).

✓

Practical implementation recommendations that translate science into actionable contamination control.

✓

Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.

✓

Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.

Ready to request your assessment?

Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.

Frequently Asked Questions

Creosote Oil Acenaphthene Fraction is a coal tar distillation fraction rich in polycyclic aromatic hydrocarbons such as acenaphthene. It is used as a component of creosote wood preservatives and as an industrial chemical feedstock. Because coal tar derived products can contain carcinogenic constituents, genotoxicity and dermal and inhalation exposure are important considerations.

A PDE or ADE sets a health-based limit on daily exposure to Creosote Oil Acenaphthene Fraction from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.

The OEL gives a scientific benchmark for evaluating workplace exposure. Combined with exposure monitoring, engineering controls, and safe handling procedures, it helps organizations manage inhalation risk during operations such as dispensing, granulation, and cleaning. It should sit within a broader occupational risk assessment.

Yes. Without a full drug data package, a limit for Creosote Oil Acenaphthene Fraction can still be derived from the available studies, read-across from structurally related compounds, structure-based evaluation and clearly documented assumptions. Where uncertainty remains, more conservative adjustment factors or a banding approach may be applied, and the rationale is recorded in the report.

The PDE provides the health-based starting point for calculating the maximum allowable carryover of Creosote Oil Acenaphthene Fraction into the next product made in shared equipment. Cleaning limits derived from it, together with suitable analytical methods and sampling, help demonstrate that residues are reduced to a level not expected to pose a risk to patients.

An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.

An OEB places Creosote Oil Acenaphthene Fraction in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.

Published toxicity data can be limited for some substances. A risk-based approach can then draw on related compounds, structure-based evaluation, and the data that do exist, with each assumption documented. For potentially mutagenic compounds, ICH M7 principles may be applied where applicable.

Carryover is evaluated by comparing the health-based limit for Creosote Oil Acenaphthene Fraction with the amount that could transfer into the next product through shared equipment. The calculation takes into account the batch size and daily dose of the following product, the shared equipment surface area and the cleaning process, so that residues can be kept below a level of concern.

Operations such as charging, transfer, sampling, milling and equipment cleaning can each create different opportunities for exposure to Creosote Oil Acenaphthene Fraction. The assessment considers the quantity handled, the physical form, the duration and frequency of tasks, and the controls in place, so that containment and protective measures are proportionate to the actual handling risk.

Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.

Use the Request Your Assessment option on this page and add Creosote Oil Acenaphthene Fraction to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.

Book a Demo